---
title: "COMPASS Pathways plc 1Q 2026: Revenue $91.2M, EPS ($0.3) — 10-Q Summary"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/286244200.md"
description: "COMPASS Pathways plc reported a significant revenue increase to $91.2M in Q1 2026, compared to a loss of $17.98M in the same quarter last year. The diluted EPS was ($0.3), an improvement from ($0.24) year-over-year. Key highlights include completion of Phase 3 trials, FDA's rolling review for COMP360, and initiation of a Phase 2b/3 PTSD trial. The company is also preparing for a potential commercial launch, contingent on final Phase 3 data."
datetime: "2026-05-13T10:41:00.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/286244200.md)
  - [en](https://longbridge.com/en/news/286244200.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/286244200.md)
---

# COMPASS Pathways plc 1Q 2026: Revenue $91.2M, EPS ($0.3) — 10-Q Summary

COMPASS Pathways plc reported first-quarter 2026 results showing a swing to positive results, with revenue of $91.2M and diluted EPS of ($0.3) compared with revenue of ($17.98M) and diluted EPS of ($0.24) in the year-ago quarter, according to the company's 10-Q filing.

**Financial Highlights**

Metric

Current quarter

Prior year quarter

YoY change

Revenue¹

$91.2M

($17.98M)

607.2%

Net income²

$91.2M

($17.86M)

610.5%

Diluted EPS³

($0.3)

($0.24)

(25%)

_¹ Reported as “Comprehensive income (loss)”. ² Reported as “Net income (loss)”. ³ Reported as “loss per share attributable to ordinary shareholders”._

**Business Highlights**

-   Clinical milestones: Completed Phase 3 COMP005 and COMP006 primary endpoints (25mg vs comparators) with statistically significant improvements on MADRS.
-   Regulatory progress: FDA granted rolling review and issued a Commissioner’s National Priority Voucher for COMP360 in treatment-resistant depression (TRD).
-   Pipeline expansion: Initiated a Phase 2b/3 PTSD trial following positive open-label Phase 2 safety and efficacy signals published in a peer-reviewed journal.
-   Operational scaling: Company is preparing for potential commercial launch with manufacturing scale-up, clinician training and commercial preparedness contingent on final Phase 3 data.

Original SEC Filing: COMPASS Pathways plc \[ CMPS \] - 10-Q - May. 13, 2026

**Disclaimer**

This is an AI-powered summary. It may contain inaccuracies. Consider verifying important information with the source. Please note this summary is solely based on documents filed with the SEC.

### Related Stocks

- [CMPS.US](https://longbridge.com/en/quote/CMPS.US.md)

## Related News & Research

- [H.C. Wainwright Sticks to Their Buy Rating for COMPASS Pathways (CMPS)](https://longbridge.com/en/news/286590906.md)
- [Compass Pathways Announces First Quarter 2026 Financial Results and Business Highlights | CMPS Stock News](https://longbridge.com/en/news/286244376.md)
- [Google's latest AI flex came with Silicon Valley's new favorite word](https://longbridge.com/en/news/286951990.md)
- [Allstate estimates April catastrophe losses at $870 million from wind, hail events](https://longbridge.com/en/news/287212811.md)
- [UK's Compass Pathways Q1 operating income beats estimates as expenses fall](https://longbridge.com/en/news/286243475.md)